A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age

Trial Profile

A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine±OMV, When Administered to Healthy Infants at 2, 4, 6 and/or 12 Months of Age

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Meningococcal vaccine group B (Primary) ; Meningococcal vaccine group B OMV Novartis (Primary) ; Aluminium hydroxide
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 04 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record (Parent trial: NCT00381615).
    • 13 Jan 2010 New source identified and integrated (United Kingdom Clinical Research Network).
    • 13 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top